Aclaris Therapeutics, Inc. (ACRS): Price and Financial Metrics

Aclaris Therapeutics, Inc. (ACRS): $8.35

0.10 (+1.21%)

POWR Rating

Component Grades














  • Sentiment is the dimension where ACRS ranks best; there it ranks ahead of 70.43% of US stocks.
  • ACRS's strongest trending metric is Stability; it's been moving down over the last 177 days.
  • ACRS's current lowest rank is in the Stability metric (where it is better than 9.02% of US stocks).

ACRS Stock Summary

  • For ACRS, its debt to operating expenses ratio is greater than that reported by just 4.61% of US equities we're observing.
  • ACRS's price/sales ratio is 17.96; that's higher than the P/S ratio of 94.06% of US stocks.
  • Revenue growth over the past 12 months for ACLARIS THERAPEUTICS INC comes in at 340.05%, a number that bests 97.68% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to ACLARIS THERAPEUTICS INC, a group of peers worth examining would be CARA, ENTA, CRNX, IMTX, and AFMD.
  • ACRS's SEC filings can be seen here. And to visit ACLARIS THERAPEUTICS INC's official web site, go to

ACRS Valuation Summary

  • ACRS's price/earnings ratio is -6.1; this is 126.29% lower than that of the median Healthcare stock.
  • Over the past 91 months, ACRS's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ACRS.

Stock Date P/S P/B P/E EV/EBIT
ACRS 2023-03-24 18.0 2.7 -6.1 -5.6
ACRS 2023-03-23 18.3 2.8 -6.3 -5.7
ACRS 2023-03-22 17.7 2.7 -6.1 -5.5
ACRS 2023-03-21 18.5 2.8 -6.3 -5.8
ACRS 2023-03-20 17.8 2.7 -6.1 -5.6
ACRS 2023-03-17 17.7 2.7 -6.1 -5.5

ACRS Growth Metrics

    The 5 year net cashflow from operations growth rate now stands at -78.19%.
  • Its year over year net income to common stockholders growth rate is now at -26.05%.
  • Its 4 year cash and equivalents growth rate is now at 128.04%.
Over the past 70 months, ACRS's revenue has gone up $29,752,000.

The table below shows ACRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 29.752 -67.567 -86.908
2022-09-30 23.5 -65.527 -82.077
2022-06-30 6.141 -68.316 -83.271
2022-03-31 6.437 -60.871 -80.9
2021-12-31 6.761 -52.134 -90.865
2021-09-30 6.84 -43.916 -81.234

ACRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACRS has a Quality Grade of D, ranking ahead of 11.05% of graded US stocks.
  • ACRS's asset turnover comes in at 0.045 -- ranking 329th of 680 Pharmaceutical Products stocks.
  • IONS, INBP, and CYTK are the stocks whose asset turnover ratios are most correlated with ACRS.

The table below shows ACRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.045 0.255 -0.798
2021-03-31 0.070 0.261 -1.118
2020-12-31 0.080 0.208 -1.456
2020-09-30 0.068 0.187 -1.659
2020-06-30 0.050 0.184 -1.897
2020-03-31 0.065 0.377 -2.002

ACRS Price Target

For more insight on analysts targets of ACRS, see our ACRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $34.80 Average Broker Recommendation 1.25 (Strong Buy)

ACRS Stock Price Chart Interactive Chart >

Price chart for ACRS

ACRS Price/Volume Stats

Current price $8.35 52-week high $18.96
Prev. close $8.25 52-week low $5.77
Day low $8.21 Volume 126,537
Day high $8.39 Avg. volume 1,046,391
50-day MA $11.92 Dividend yield N/A
200-day MA $14.89 Market Cap 556.89M

Aclaris Therapeutics, Inc. (ACRS) Company Bio

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, Pennsylvania.

ACRS Latest News Stream

Event/Time News Detail
Loading, please wait...

ACRS Latest Social Stream

Loading social stream, please wait...

View Full ACRS Social Stream

Latest ACRS News From Around the Web

Below are the latest news stories about ACLARIS THERAPEUTICS INC that investors may wish to consider to help them evaluate ACRS as an investment opportunity.

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 1:00 PM ET. A webcast of the fireside chat may be accessed through the “Events” pa

Yahoo | March 27, 2023

Lab Notes: Fox Chase Cancer Center researcher gets $1M grant; NRx raises funds

Recent Philadelphia-area life sciences includes Aclaris and Incyte suffering setbacks with experimental therapies.

Yahoo | March 10, 2023

As Focus Shifts From Hidradenitis Suppurativa, Analyst Seems Bullish On Aclaris

Aclaris Therapeutics Inc (NASDAQ: ACRS) flunked a 12-week, Phase 2a study of zunsemetinib (ATI-450) for moderate to severe hidradenitis suppurativa. The study did not meet its primary endpoint of change from baseline in inflammatory nodule/abscess count (AN) of zunsemetinib 50mg BID versus placebo at week 12. The study did not meet the secondary efficacy endpoints. William Blair writes that while the negative results are disappointing and represent a setback, it does not change the thesis that z

Yahoo | March 6, 2023

These 2 Biotech Stocks Made Big Monday Moves

The stock market got off to a solid start on Monday, although there was a considerable disparity among different kinds of stocks. On the upside, BridgeBio Pharma (NASDAQ: BBIO) soared after releasing promising data on one of its treatments, while Aclaris Therapeutics (NASDAQ: ACRS) went the other direction on less-encouraging trial results. Shares of BridgeBio Pharma jumped almost 60% in midafternoon trading on Monday.

Yahoo | March 6, 2023

Why Aclaris Therapeutics Stock Is Plunging Today

Aclaris Therapeutics Inc (NASDAQ: ACRS) announced preliminary topline results from a 12-week, Phase 2a study of zunsemetinib (ATI-450) for moderate to severe hidradenitis suppurativa. The study did not meet its primary endpoint of change from baseline in inflammatory nodule/abscess count (AN) of zunsemetinib 50mg BID versus placebo at week 12. The study also did not meet the secondary efficacy endpoints assessed in the topline data, including the percentage of patients achieving HiSCR-50. The pl

Yahoo | March 6, 2023

Read More 'ACRS' Stories Here

ACRS Price Returns

1-mo -32.99%
3-mo -46.98%
6-mo -46.95%
1-year -52.66%
3-year 718.63%
5-year -52.34%
YTD -46.98%
2022 8.32%
2021 124.73%
2020 242.33%
2019 -74.42%
2018 -70.03%

Continue Researching ACRS

Want to see what other sources are saying about Aclaris Therapeutics Inc's financials and stock price? Try the links below:

Aclaris Therapeutics Inc (ACRS) Stock Price | Nasdaq
Aclaris Therapeutics Inc (ACRS) Stock Quote, History and News - Yahoo Finance
Aclaris Therapeutics Inc (ACRS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8863 seconds.